An update of clinical experience with the quadrivalent meningococcal ACWY-CRM conjugate vaccine
Open Access
- 27 September 2018
- journal article
- research article
- Published by Taylor & Francis in Expert Review of Vaccines
- Vol. 17 (10) , 865-880
Abstract
Menveo, quadrivalent meningococcal ACWY-CRM conjugate vaccine, was first licensed in 2010 in the United States and has a long track record of immunogenicity and safety in all age groups, including infants from 2 months of age. This review presents clinical and post-marketing experience with MenACWY-CRM from 32 studies conducted in 20 countries that included individuals aged from 2 months to 75 years. This decade has seen an increased number of countries reporting serogroup W ST-11 clonal complex outbreaks of invasive meningococcal disease. As infant vaccination programs targeting the meningococcus are reevaluated, the role of quadrivalent meningococcal vaccines including MenACWY-CRM will be expanded. MenACWY-CRM was immunogenic in all populations and age groups studied, regardless of country of origin. MenACWY-CRM can be coadministered with many routinely used infant, toddler and adolescent vaccines, and traveler vaccines in adults, allowing for flexible use within national immunization programs and recommendations. Antibody persistence has been demonstrated up to 5 years post vaccination in all age groups. Booster doses induced robust increases in antibody titers for all four serogroups, indicative of effective priming and induction of immunological memory. The acceptable safety profile of MenACWY-CRM has been confirmed in large post-marketing safety studies.Keywords
Funding Information
- GlaxoSmithKline Biologicals SA
This publication has 64 references indexed in Scilit:
- Antibody Persistence and Response to a Booster Dose of a Quadrivalent Conjugate Vaccine for Meningococcal Disease in AdolescentsThe Pediatric Infectious Disease Journal, 2013
- Safety and Immunogenicity of a Novel Quadrivalent Meningococcal CRM-conjugate Vaccine Given Concomitantly With Routine Vaccinations in InfantsThe Pediatric Infectious Disease Journal, 2012
- Critical appraisal of a quadrivalent CRM197 conjugate vaccine against meningococcal serogroups A, C W-135 and Y (Menveo®) in the context of treatment and prevention of invasive diseaseInfection and Drug Resistance, 2011
- Effectiveness of Serogroup C Meningococcal Conjugate VaccineThe Pediatric Infectious Disease Journal, 2011
- Early Estimate of the Effectiveness of Quadrivalent Meningococcal Conjugate VaccineThe Pediatric Infectious Disease Journal, 2011
- Immunogenicity and Safety of a Multicomponent Meningococcal Serogroup B Vaccine and a Quadrivalent Meningococcal CRM 197 Conjugate Vaccine against Serogroups A, C, W-135, and Y in Adults Who Are at Increased Risk for Occupational Exposure to Meningococcal IsolatesClinical and Vaccine Immunology, 2011
- Persistence of immune responses after a single dose of Novartis meningococcal serogroup A, C, W-135 and Y CRM-197 conjugate vaccine (Menveo®) or Menactra® among healthy adolescentsHuman Vaccines, 2010
- Comparison of the safety and immunogenicity of an investigational and a licensed quadrivalent meningococcal conjugate vaccine in children 2–10 years of ageVaccine, 2010
- Randomized Trial on the Safety, Tolerability, and Immunogenicity of MenACWY-CRM, an Investigational Quadrivalent Meningococcal Glycoconjugate Vaccine, Administered Concomitantly with a Combined Tetanus, Reduced Diphtheria, and Acellular Pertussis Vaccine in Adolescents and Young AdultsClinical and Vaccine Immunology, 2010
- Global epidemiology of meningococcal diseaseVaccine, 2009